Surefire Medical touted data today from a retrospective analysis of 85 bridge-to-transplant liver cancer patients treated with transarterial chemoembolization.

The data showed that therapy delivered using the Surefire infusion system yielded an 80% complete response in 1 treatment compared to 52% with a standard endhole microcatheter. The analysis also demonstrated a lower recurrence rate of liver cancer at 1 month for patients that used Surefire’s technology instead of a conventional microcatheter.

Get the full story at our sister site, Drug Delivery Business News.